ClinicalTrials.gg
CompletedNCT02161575SAFARIUpdated Feb 15, 2019Results posted

Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD

A Phase 4 interventional study of Ranibizumab in Neovascular Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 28 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
103
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
47th of 124
103 · median 64
Started
2014
with 9 others
Phase 4
33 of 125
none open now
Registered
90th of 125
by date
Lead sponsor
15 of 125
Novartis Pharmaceuticals

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 47th largest by enrollment of the 124 interventional ones that give a count, is one of 10 that started in 2014, is one of 33 in phase 4, and was the 90th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

AMD (Age Related Macular Degeneration) is the leading cause of severe visual loss and blindness registration in the UK . It is a disease which affects the retina (the nerve and blood vessel network at the back of the eye responsible for vision). Patients can suffer with severe visual loss and have difficulties with every day tasks such as recognising faces, reading \& driving.

There are two variations of the disease, a 'dry' type \& a 'wet' type also known as neovascular AMD (nAMD). In wet/nAMD new vessels grow from the blood supply underneath the retina, in part due to higher than normal levels of a protein called Vascular Endothelial Growth Factor (VEGF). Since the introduction of drugs which block VEGF, visual outcomes for patients with wAMD have dramatically improved.

There are 2 widely used treatments; ranibizumab and aflibercept. Whilst the majority of patients have a successful outcome with treatment, many patients experience suboptimal response. This study evaluated if these patients experience a benefit from a switch to a different antiVEGF drug treatment.

In this study nAMD patients who are showing no or poor to response to treatment with aflibercept were switched to ranibizumab to assess if there is any benefit in terms of treatment outcomes.

Patients visited the hospital clinic 8 times over the 7 - 8 month study period. Monthly ranibizumab injections were given for the first 3 months, then monthly as required for the next 3 months.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration

Keywords

  • Macular degeneration
  • age-related macular degeneration (ARMD)
  • vision loss
  • macula damage
  • retina damage
  • dry macular degeneration
  • wet macular degeneration
  • AMD
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Best corrected visual acuity (BCVA) ≥23 ETDRS letters in study eye
  • Evidence of active choroidal neovascularisation (CNV) involving the center of the fovea in study eye Patient subgroup specific inclusion criteria: - Group 1. Primary treatment failure
  • Initiated treatment with aflibercept \<130 days prior to the Screening Visit.
  • No increase in BCVA (≥5 letters) since commencing treatment with aflibercept.
  • Disease activity has never been controlled in the study eye after initiating aflibercept as defined by at least one of the following: evidence of unchanged or increasing retinal or subretinal fluid; new PED; unchanged or increasing size of preexisting PED.

Group 2. Suboptimal treatment response

  • Aflibercept commenced ≥6 months prior to the Screening Visit.
  • Received ≥3 aflibercept injections into the study eye within 6 months of the Screening Visit.
  • Evidence of previous reduced disease activity (as defined by reduction of ≥50μm in Central Subfield Retinal Thickness on OCT) noted in the study eye after initiating aflibercept.
  • At Screening Visit, disease activity has worsened (as defined by increasing retinal* or subretinal fluid, or new or increasing size of PED) in the study eye compared to prior visits.

Exclusion criteria

Exclusion Criteria:

  • History of cerebrovascular accident, or myocardial infarction within 3 months of the Screening visit.
  • Uncontrolled blood pressure
  • Evidence of bilateral active CNV during the Screening Period or at Baseline requiring bilateral antiVEGF injections.
  • Prior intravitreal injection of ranibizumab or bevacizumab into the study eye and/or prior intravitreal injection of bevacizumab into the fellow eye.
  • Cataract (if causing significant visual impairment), aphakia, severe vitreous hemorrhage, rhegmatogenous retinal detachment, proliferative retinopathy or choroidal neovascularization of any other cause than wet AMD (e.g. ocular histoplasmosis, pathologic myopia (≥8 dioptres)) at the time of Screening and Baseline.
  • Irreversible structural damage involving the center of the fovea (e.g. advanced fibrosis or geographic atrophy) which in the opinion of the Investigator is sufficient to irreversibly impair visual acuity.
  • Polypoidal choroidal vasculopathy (PCV), RPE tear, central serous retinopathy (CSR), or significant vitreomacular traction identified during Screening period or within 4 months of Baseline visit.
  • Unable to obtain at Screening OCT images of sufficient quality to be analyzed
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Ranibizumab

    All patients received 3 monthly intraveal injections of 0.5mg ranibizumab followed by monthly injections of ranibizumab 0.5mg for a further 3 months on a prn (as required) basis, as determined by the study doctor.

    Drug: Ranibizumab

Interventions

  • Intraveal injections of 0.5mg ranibizumab

06

What researchers measure

Primary outcomes

  1. Change in Central Subfield Retinal Thickness (CSRT) From Baseline to Day 90.

    Measurement of the change in CSRT, determined by high definition optical coherence tomography (HD-OCT) after 3 monthly injections of ranibizumab. OCT is a non-invasive technique which can determine and measure thickness of the retina. A negative change from Baseline indicates an improvement (less retinal fluid and lower disease activity). Data collected on the study eye were used for the evaluation of efficacy.

    Time frame: Baseline and Day 90

Secondary outcomes

  1. Change in Subfoveal Retinal Thickness (SRT) From Baseline to Day 180

    Measurement of change in SRT from Baseline to Day 180 as determined by high definition optical coherence tomography (HD-OCT). A reduction indicates an improvement in overall disease activity. Data collected on the study eye were used for the evaluation of efficacy.

    Time frame: Baseline and Day 180

  2. Change in Central Subfield Retinal Thickness (CSRT) From Baseline to Day 180

    Measurement of change in CSRT from Baseline to Day 180 as determined by high definition optical coherence tomography (HD-OCT). A reduction indicates an improvement in overall disease activity. Data collected on the study eye were used for the evaluation of efficacy.

    Time frame: Baseline and Day 180

  3. Change in Central Subfield Retinal Volume (CSRV) From Baseline to Day 180

    Measurement of change in CSRV from Baseline to Day 180 as determined by high definition optical coherence tomography (HD-OCT). A reduction indicates an improvement in overall disease activity. Data collected on the study eye were used for the evaluation of efficacy.

    Time frame: Baseline and Day 180

  4. Number of Patients With Intraretinal Fluid Assessed at Baseline and Day 180

    Presence or absence of qualitative OCT parameter Intraretinal Fluid. Data collected on the study eye were used for the evaluation of efficacy.

    Time frame: Baseline and Day 180

  5. Number of Patients With Subretinal Fluid Assessed at Baseline and Day 180

    Presence or absence of qualitative OCT parameter Subretinal Fluid. Data collected on the study eye were used for the evaluation of efficacy.

    Time frame: Baseline to Day 180

  6. Number of Patients With Intraretinal/Subretinal Fluid Within the Central Subfield Fluid Assessed at Baseline and Day 180

    Presence or absence of qualitative OCT parameter Intraretinal/Subretinal Fluid Within the Central Subfield. Data collected on the study eye were used for the evaluation of efficacy.

    Time frame: Baseline and Day 180

  7. Number of Patients With Pigment Epithelial Detachments Assessed at Baseline and Day 180

    Presence or absence of qualitative OCT parameter Pigment Epithelial Detachments. Data collected on the study eye were used for the evaluation of efficacy.

    Time frame: Baseline and Day 180

  8. Number of Patients With Dry Retina Assessed at Baseline and Day 180

    Presence or absence of qualitative OCT parameter Dry Retina. Data collected on the study eye were used for the evaluation of efficacy.

    Time frame: Baseline and Day 180

  9. Change in Maximum PED Height From Baseline to Day 180

    Change from Baseline to Day 180 in Maximum Pigment Epithelial Detachment (PED) Height. Data collected on the study eye were used for the evaluation of efficacy.

    Time frame: Baseline and Day 180

  10. Change in Maximum PED Diameter From Baseline to Day 180

    Change from Baseline to Day 180 in Maximum Pigment Epithelial Detachment (PED) Diameter. Data collected on the study eye were used for the evaluation of efficacy.

    Time frame: Baseline and Day 180

  11. Change in Maximum IRC Height From Baseline to Day 180

    Change from Baseline to Day 180 in Maximum Intraretinal Cyst (IRC) Height. Data collected on the study eye were used for the evaluation of efficacy.

    Time frame: Baseline and Day 180

  12. Change in Best Corrected Visual Acuity (BCVA) in the Study Eye

    BCVA was assessed as letters read and measured in a sitting position using subjective refraction and Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters.

    Time frame: Baseline, Day 90 and Day 180

  13. Change in ETDRS Letters for Study Eye From Baseline to Day 180

    Number of patients gaining at least 15 letters from Baseline to Day 180

    Time frame: Baseline and Day 180

  14. Incidence of Ocular TEAEs in the Study Eye Reported by ≥2% Patients From Baseline to Day 180

    Incidence of ocular Treatment Emergent Adverse Events (TEAEs) in the study eye reported by ≥2% patients by preferred term.

    Time frame: Baseline to Day 180

07

Results

Posted Feb 15, 2019

Participant flow

Patients were recruited from 22 sites located in the United Kingdom and 6 sites located in Germany. A total of 103 patients received at least 1 dose of study drug.

Participant flow — Overall Study
MilestoneRanibizumab
Started103
Full analysis set (fas) population100
Safety (saf) population100
Completed92
Not completed11
Withdrew: Protocol violation8
Withdrew: Lack of efficacy1
Withdrew: Adverse event2

Outcome measures

PrimaryChange in Central Subfield Retinal Thickness (CSRT) From Baseline to Day 90.

Measurement of the change in CSRT, determined by high definition optical coherence tomography (HD-OCT) after 3 monthly injections of ranibizumab. OCT is a non-invasive technique which can determine and measure thickness of the retina. A negative change from Baseline indicates an improvement (less retinal fluid and lower disease activity). Data collected on the study eye were used for the evaluation of efficacy.

Time frame:
Baseline and Day 90
Reported as:
Median · micrometer
Change in Central Subfield Retinal Thickness (CSRT) From Baseline to Day 90.
micrometerRanibizumab
Baseline384.00 (154.0 to 975.0)
Day 90318.00 (170.0 to 832.0)
Change from Baseline to Day 90-30.75 (-386.0 to 78.0)
Statistical analysis
  • Ranibizumab · Wilcoxon (Mann-Whitney) · p = <0.0001 · Median difference (final values): -30.75 · 95% CI -59.50 to -20.50Confidence Interval for the Median Change form Baseline
SecondaryChange in Subfoveal Retinal Thickness (SRT) From Baseline to Day 180

Measurement of change in SRT from Baseline to Day 180 as determined by high definition optical coherence tomography (HD-OCT). A reduction indicates an improvement in overall disease activity. Data collected on the study eye were used for the evaluation of efficacy.

Time frame:
Baseline and Day 180
Reported as:
Median · micrometer
Change in Subfoveal Retinal Thickness (SRT) From Baseline to Day 180
micrometerRanibizumab
SRT at Baseline346.00 (69.0 to 944.5)
SRT at Day 180302.00 (41.5 to 876.5)
SRT change from Baseline to Day 180-23.50 (-464.0 to 306.5)
SecondaryChange in Central Subfield Retinal Thickness (CSRT) From Baseline to Day 180

Measurement of change in CSRT from Baseline to Day 180 as determined by high definition optical coherence tomography (HD-OCT). A reduction indicates an improvement in overall disease activity. Data collected on the study eye were used for the evaluation of efficacy.

Time frame:
Baseline and Day 180
Reported as:
Median · micrometer
Change in Central Subfield Retinal Thickness (CSRT) From Baseline to Day 180
micrometerRanibizumab
CSRT at Baseline384.00 (154.0 to 975.0)
CSRT at Day 180343.00 (194.0 to 842.0)
CSRT change from Baseline to Day 180-28.00 (-271.0 to 171.0)
SecondaryChange in Central Subfield Retinal Volume (CSRV) From Baseline to Day 180

Measurement of change in CSRV from Baseline to Day 180 as determined by high definition optical coherence tomography (HD-OCT). A reduction indicates an improvement in overall disease activity. Data collected on the study eye were used for the evaluation of efficacy.

Time frame:
Baseline and Day 180
Reported as:
Median · cubic micrometer
Change in Central Subfield Retinal Volume (CSRV) From Baseline to Day 180
cubic micrometerRanibizumab
CSRV at Baseline0.3050 (0.120 to 11.600)
CSRV at Day 1800.2750 (0.115 to 11.400)
CSRV change from Baseline to Day 180-0.0200 (-1.600 to 0.135)
SecondaryNumber of Patients With Intraretinal Fluid Assessed at Baseline and Day 180

Presence or absence of qualitative OCT parameter Intraretinal Fluid. Data collected on the study eye were used for the evaluation of efficacy.

Time frame:
Baseline and Day 180
Reported as:
Count of participants · Participants
Number of Patients With Intraretinal Fluid Assessed at Baseline and Day 180
ParticipantsRanibizumab
Baseline — Yes, Definitive32
Baseline — Yes, Subtle11
Baseline — No56
Baseline — Questionable1
Day 180 — Yes, Definitive24
Day 180 — Yes, Subtle15
Day 180 — No55
Day 180 — Questionable0
SecondaryNumber of Patients With Subretinal Fluid Assessed at Baseline and Day 180

Presence or absence of qualitative OCT parameter Subretinal Fluid. Data collected on the study eye were used for the evaluation of efficacy.

Time frame:
Baseline to Day 180
Reported as:
Count of participants · Participants
Number of Patients With Subretinal Fluid Assessed at Baseline and Day 180
ParticipantsRanibizumab
Baseline — Yes, Definitive83
Baseline — Yes, Subtle5
Baseline — No12
Day 180 — Yes, Definitive49
Day 180 — Yes, Subtle15
Day 180 — No30
SecondaryNumber of Patients With Intraretinal/Subretinal Fluid Within the Central Subfield Fluid Assessed at Baseline and Day 180

Presence or absence of qualitative OCT parameter Intraretinal/Subretinal Fluid Within the Central Subfield. Data collected on the study eye were used for the evaluation of efficacy.

Time frame:
Baseline and Day 180
Reported as:
Count of participants · Participants
Number of Patients With Intraretinal/Subretinal Fluid Within the Central Subfield Fluid Assessed at Baseline and Day 180
ParticipantsRanibizumab
Baseline — Yes, Definitive38
Baseline — Yes, Subtle6
Baseline — No5
Baseline — Questionable1
Baseline — NA50
Day 180 — Yes, Definitive26
Day 180 — Yes, Subtle12
Day 180 — No15
Day 180 — Questionable1
Day 180 — NA40
SecondaryNumber of Patients With Pigment Epithelial Detachments Assessed at Baseline and Day 180

Presence or absence of qualitative OCT parameter Pigment Epithelial Detachments. Data collected on the study eye were used for the evaluation of efficacy.

Time frame:
Baseline and Day 180
Reported as:
Count of participants · Participants
Number of Patients With Pigment Epithelial Detachments Assessed at Baseline and Day 180
ParticipantsRanibizumab
Baseline — Yes, Definitive86
Baseline — Yes, Subtle2
Baseline — No12
Baseline — Not gradable0
Day 180 — Yes, Definitive80
Day 180 — Yes, Subtle4
Day 180 — No8
Day 180 — Not gradable2
SecondaryNumber of Patients With Dry Retina Assessed at Baseline and Day 180

Presence or absence of qualitative OCT parameter Dry Retina. Data collected on the study eye were used for the evaluation of efficacy.

Time frame:
Baseline and Day 180
Reported as:
Count of participants · Participants
Number of Patients With Dry Retina Assessed at Baseline and Day 180
ParticipantsRanibizumab
Baseline — Yes, Definitive0
Baseline — No100
Day 180 — Yes, Definitive0
Day 180 — No94
SecondaryChange in Maximum PED Height From Baseline to Day 180

Change from Baseline to Day 180 in Maximum Pigment Epithelial Detachment (PED) Height. Data collected on the study eye were used for the evaluation of efficacy.

Time frame:
Baseline and Day 180
Reported as:
Median · micrometer
Change in Maximum PED Height From Baseline to Day 180
micrometerRanibizumab
Baseline236.00 (66.5 to 674.0)
Day 180203.50 (63.5 to 705.0)
Change from Baseline to Day 180-2.50 (-336.5 to 131.0)
SecondaryChange in Maximum PED Diameter From Baseline to Day 180

Change from Baseline to Day 180 in Maximum Pigment Epithelial Detachment (PED) Diameter. Data collected on the study eye were used for the evaluation of efficacy.

Time frame:
Baseline and Day 180
Reported as:
Median · micrometer
Change in Maximum PED Diameter From Baseline to Day 180
micrometerRanibizumab
Baseline2205.00 (0.0 to 4877.0)
Day 1802428.00 (471.0 to 4683.0)
Change from Baseline to Day 18059.50 (-1007.0 to 2756.0)
SecondaryChange in Maximum IRC Height From Baseline to Day 180

Change from Baseline to Day 180 in Maximum Intraretinal Cyst (IRC) Height. Data collected on the study eye were used for the evaluation of efficacy.

Time frame:
Baseline and Day 180
Reported as:
Median · micrometer
Change in Maximum IRC Height From Baseline to Day 180
micrometerRanibizumab
Baseline121.50 (21.0 to 280.5)
Day 180105.50 (25.5 to 485.0)
Change from Baseline to Day 1800.00 (-223.5 to 235.0)
SecondaryChange in Best Corrected Visual Acuity (BCVA) in the Study Eye

BCVA was assessed as letters read and measured in a sitting position using subjective refraction and Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters.

Time frame:
Baseline, Day 90 and Day 180
Reported as:
Median · letters
Change in Best Corrected Visual Acuity (BCVA) in the Study Eye
lettersRanibizumab
Baseline71.5 (36 to 90)
Day 9074.0 (32 to 87)
Day 18075.0 (32 to 90)
Change from Baseline to Day 1801.0 (-31 to 35)
Change from Day 90 to Day 1800.0 (-25 to 24)
SecondaryChange in ETDRS Letters for Study Eye From Baseline to Day 180

Number of patients gaining at least 15 letters from Baseline to Day 180

Time frame:
Baseline and Day 180
Reported as:
Count of participants · Participants
Change in ETDRS Letters for Study Eye From Baseline to Day 180
ParticipantsRanibizumab
>=15 (Gain of at least 15 letters)11
10 to <156
5 to <1017
0 to <525
>-15 to <031
<=-15 (Loss of at least 15 letters)7
NA3
SecondaryIncidence of Ocular TEAEs in the Study Eye Reported by ≥2% Patients From Baseline to Day 180

Incidence of ocular Treatment Emergent Adverse Events (TEAEs) in the study eye reported by ≥2% patients by preferred term.

Time frame:
Baseline to Day 180
Reported as:
Count of participants · Participants
Incidence of Ocular TEAEs in the Study Eye Reported by ≥2% Patients From Baseline to Day 180
ParticipantsRanibizumab
Eye pain3
Visual impairment3
Blepharitis2
Posterior capsule opacification2
Intraocular pressure increased3

Adverse events

Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit up to approximately 6 months.. Non-serious events are listed at a 1.9% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab0/100 (0%)10/100 (10%)52/100 (52%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventRanibizumab
FALLInjury, poisoning and procedural complications3/100
ANAEMIABlood and lymphatic system disorders1/100
ACUTE MYOCARDIAL INFARCTIONCardiac disorders1/100
ATRIAL FIBRILLATIONCardiac disorders1/100
ATRIAL FLUTTERCardiac disorders1/100
RETINAL HAEMORRHAGEEye disorders1/100
DIARRHOEAGastrointestinal disorders1/100
UPPER GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders1/100
VOMITINGGastrointestinal disorders1/100
NON-CARDIAC CHEST PAINGeneral disorders1/100
Most frequent other events
Showing 10 of 22
Most frequent other events
EventRanibizumab
NASOPHARYNGITISInfections and infestations9/100
LOWER RESPIRATORY TRACT INFECTIONInfections and infestations7/100
COUGHRespiratory, thoracic and mediastinal disorders7/100
BLEPHARITISEye disorders6/100
BLOOD PRESSURE INCREASEDInvestigations4/100
DRY EYEEye disorders3/100
EYE PAINEye disorders3/100
VISUAL IMPAIRMENTEye disorders3/100
INTRAOCULAR PRESSURE INCREASEDInvestigations3/100
BACK PAINMusculoskeletal and connective tissue disorders3/100

Baseline characteristics

FAS

Age, Continuous
Age, Continuous(years)Ranibizumab
Mean77 ± 6.51
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab
Female55
Male45
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ranibizumab
Caucasian99
Asian1
08

Study locations

28 sites
  • Novartis Investigative Site
    Bonn, 53127, Germany
  • Novartis Investigative Site
    Karlsruhe, 76135, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Mühlheim, 45468, Germany
  • Novartis Investigative Site
    München, 80336, Germany
  • Novartis Investigative Site
    Darlington, Durham DL3 6HX, United Kingdom
  • Novartis Investigative Site
    Harlow, Essex CM20 1QX, United Kingdom
  • Novartis Investigative Site
    Canterbury, Kent CT1 3NG, United Kingdom
  • Novartis Investigative Site
    Aberdeen, Scotland AB25 2ZN, United Kingdom
  • Novartis Investigative Site
    Ipswich, Suffolk IP4 5PD, United Kingdom
  • Novartis Investigative Site
    Frimley, Surrey GU16 7UJ, United Kingdom
  • Novartis Investigative Site
    Bradford, West Yorkshire BD9 6RJ, United Kingdom
  • Novartis Investigative Site
    Belfast, BT12 6BA, United Kingdom
  • Novartis Investigative Site
    East Kilbride, G75 8RG, United Kingdom
  • Novartis Investigative Site
    Glasgow, G12 OYN, United Kingdom
  • Novartis Investigative Site
    Great Yarmouth, NR31 6LA, United Kingdom
  • Novartis Investigative Site
    Harrogate, HG2 7SX, United Kingdom
  • Novartis Investigative Site
    Liverpool, L7 8XP, United Kingdom
  • Novartis Investigative Site
    London, EC1V 2PD, United Kingdom
  • Novartis Investigative Site
    London, NW1 5QH, United Kingdom
  • Novartis Investigative Site
    London, SE5 9RS, United Kingdom
  • Novartis Investigative Site
    Manchester, M13 9WL, United Kingdom
  • Novartis Investigative Site
    Oxford, OX3 9DU, United Kingdom
  • Novartis Investigative Site
    Southampton, SO16 6YD, United Kingdom
  • Novartis Investigative Site
    Sunderland, SR2 9HP, United Kingdom
  • Novartis Investigative Site
    Uxbridge, UB8 3NN, United Kingdom
  • Novartis Investigative Site
    York, YO31 8HE, United Kingdom
09

References and documents

Publications

  • Gale RP, Pearce I, Eter N, Ghanchi F, Holz FG, Schmitz-Valckenberg S, Balaskas K, Burton BJL, Downes SM, Eleftheriadis H, George S, Gilmour D, Hamilton R, Lotery AJ, Patel N, Prakash P, Santiago C, Thomas S, Varma D, Walters G, Williams M, Wolf A, Zakri RH, Igwe F, Ayan F. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Br J Ophthalmol. 2020 Apr;104(4):493-499. doi: 10.1136/bjophthalmol-2019-314251. Epub 2019 Aug 5. PubMed 31383649 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Sep 2017, 36 months.

Results were first posted in Feb 2019, 1 year 5 months after primary completion.

Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 36 months is above that.

Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2014
First posted
Jun 11, 2014
StartActual
Aug 28, 2014
Primary completionActual
Sep 14, 2017
CompletionActual
Sep 14, 2017
Results first posted
Feb 15, 2019
Last update
Feb 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02161575
Responsible party
Sponsor
First posted
Jun 11, 2014
Start date
Aug 28, 2014
Primary completion
Sep 14, 2017
Completion
Sep 14, 2017
Results posted
Feb 15, 2019
Last update
Feb 15, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion